913822-46-5

Basic information

• Product Name: 4-ThiazolecarboxaMide, N-(6-benzoyl-1H-benziMidazol-2-yl)-2-(1-thieno[3,2-d]pyriMidin-4-yl-4-piperidinyl)-
• Synonyms: 4-ThiazolecarboxaMide, N-(6-benzoyl-1H-benziMidazol-2-yl)-2-(1-thieno[3,2-d]pyriMidin-4-yl-4-piperidinyl)-;V 1810;N-(6-Benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)-4-thiazolecarboxamide;75741
• CAS NO: 913822-46-5
• Molecular Formula: C29H23N7O2S2
• Molecular Weight: 565.66862
• Product Categories: Inhibitors
• Mol File: 913822-46-5.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.483±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
• PKA: 9.11±0.10(Predicted)
• CAS DataBase Reference: 4-ThiazolecarboxaMide, N-(6-benzoyl-1H-benziMidazol-2-yl)-2-(1-thieno[3,2-d]pyriMidin-4-yl-4-piperidinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ThiazolecarboxaMide, N-(6-benzoyl-1H-benziMidazol-2-yl)-2-(1-thieno[3,2-d]pyriMidin-4-yl-4-piperidinyl)-(913822-46-5)
• EPA Substance Registry System: 4-ThiazolecarboxaMide, N-(6-benzoyl-1H-benziMidazol-2-yl)-2-(1-thieno[3,2-d]pyriMidin-4-yl-4-piperidinyl)-(913822-46-5)

Safety Data

• Hazardous Substances Data: 913822-46-5(Hazardous Substances Data)

Usage

Description

4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)is a complex organic compound with a unique molecular structure that features a thiazolecarboxamide core, a benzimidazole moiety, and a thieno[3,2-d]pyrimidinyl-piperidinyl group. 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)is characterized by its potential biological activity and may have applications in various fields, particularly in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)is used as a potent NF-κB inhibitor with an EC50 value, indicating its ability to modulate the activity of the NF-κB signaling pathway. This makes it a promising candidate for the development of therapeutic agents targeting various inflammatory and immune-related disorders.
Used in Antiviral Applications:
4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)has demonstrated its effectiveness as an inhibitor of replication for human, avian, and swine influenza virus strains in MDCK cells in a concentration-dependent manner. It also shows reversible inhibition of H5N1 and H7N7 avian influenza virus strains in human A549 cells, suggesting its potential use in the development of antiviral drugs.
Used in In Vivo Studies:
In vivo studies have shown that 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)can reduce viral mRNA and the production of IL-6 and CXCL10/IP-10 in the lungs of H5N1 infected mice when administered at a dosage of 15 mg/kg, i.p. This highlights its potential as a therapeutic agent for the treatment of influenza infections.
Used in Protective Measures Against Influenza Infections:
When administered for 7 days prior to or up to 4 days post infection, 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)has been found to be protective against H5N1 and H7N7 infection in mice. This indicates its potential use in prophylactic treatments and therapeutic interventions for influenza infections.

Relevant articles and documents

Pharmaceutical composition comprising a cytokine

The present invention relates to a pharmaceutical composition comprising, (i) a cytokine and, (ii) a compound of the general formula (Ih) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof. Exemplary cytokines are selected from the following group of cytokine families, (i) the four α-helix bundle family, which consists of, (a) the the IL-2 subfamily, (b) the interferon (IFN) subfamily and, (c) the IL-10 subfamily, (ii) the IL-1 family, (iii) the IL-17 family and, (iv) chemokines.